Sign in
Taking peoplePhase 2

Regorafenib for meningioma that has come back

Tests regorafenib against usual local care in adults with recurrent meningioma.

Key facts

Who runs it
Istituto Oncologico Veneto IRCCS
Where
Italy20 sites in 1 countryChoose a country to see its sites
Registry title
Regorafenib for Recurrent Meningioma (MIRAGE Trial)
Status
Recruiting
Phase
Phase 2
People taking part
104 people, planned
Started
23 Sept 2024
Expected to end
Mar 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Regorafenib 40 MG Oral Tablet
  • Local Standard of Care
Record updated
30 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a meningioma (a tumour of the brain's covering) that has grown again. Surgery and radiotherapy must no longer be options for them.

Age
18 years or older
Sex
All sexes
Disease stage
Meningioma confirmed by tissue test (WHO 2021 grade 1, 2 or 3). On scans, the tumour grew by more than 25% in the last 12 months, or new tumours appeared. At least 1 tumour of at least 10 x 10mm on MRI. Able to do daily activities (ECOG 0 to 1 or KPS 70). Expected to live at least 6 months.
Earlier treatment
No earlier anti-cancer drug treatment for meningioma. People cannot have more surgery or radiotherapy. After radiotherapy, the tumour must have grown at least 24 weeks after it ended. Earlier bevacizumab for radiation damage is allowed. Steroid dose of 4mg/die or less, stable or going down for 7 days.
Biomarker or test result
Stored tumour tissue must be available. Blood tests must show good blood counts, liver and kidney function.

Main reasons for not taking part

  • Tumour outside the brain, such as spinal cord, bone or distant organs
  • Another cancer in the last 3 years, except in situ or basal or squamous cell skin cancer
  • Serious heart disease, stroke in the last 6 months, or uncontrolled high blood pressure
  • Bleeding problems or serious bleeding events
  • Taking strong CYP3A4 or UGT1A9 drugs, or other active meningioma treatment outside the trial

The registry criteria, word for word

Show all 54 criteriaShow less

Who can take part

  • Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
  • Patients capable of taking oral medication
  • Subject is willing and able to adhere to the study visit schedule and other protocol requirements
  • Histological diagnosis of meningioma according to the WHO 2021 classification
  • Radiologically documented progression of any existing tumor with an estimated planar growth >25% (bidirectional) in the last 12 months or appearance of new lesions
  • Ineligible for further surgery and/or radiotherapy
  • at least 1 Measurable lesion (minimum 10 x 10mm) on baseline MRI
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1 (or KPS ³70)
  • Male or female ≥ 18 years of age
  • Subjects must have life expectancy of at least 6 months
  • Paraffin-embedded tumor tissue available (mandatory)
  • Dosage of dexamethasone or equivalent steroid within 7 days prior the randomization ≤4mg/die
  • Stable or decreasing dosage of steroids for 7 days prior to the randomization
  • Adequate cardiac function and adequate liver, renal and hematological function
  • Subject must have the following laboratory values at screening within 14 days before starting Regorafenib:
  • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14 days if subject received pegfilgrastim)
  • Hemoglobin (Hgb) ≥10 g/dL
  • Platelet count (plt) ≥100x 109/L
  • Serum potassium concentration within normal range, or correctable with supplements
  • Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST) and serum glutamate pyruvic transaminase (SGPT)/alanine aminotransferase (ALT) ≤ 3.0 x Upper Limit of Normal (ULN)
  • Serum total bilirubin ≤ 1.5 x ULN
  • Serum creatinine ≤ 1.5 x ULN or measured glomerular filtration rate (GFR) ≥ 50 mL/min/1.73 m2 using an exogenous filtration marker such as iohexol, inulin, 51Cr EDTA or 1125 iothalamate, or creatinine clearance of ≥ 50 mL/min using Cockroft-Gault equation
  • Serum albumin > 3.5 g/dL
  • PT (or INR) and APTT within normal range
  • For women who are not postmenopausal (i.e., < 2 years after last menstruation) or surgically sterile (absence of ovaries and/or uterus) and who are sexually active: agreement to use an adequate method of contraception (oral contraceptives, intrauterine contraceptive device, or barrier method of contraception in conjunction with spermicidal jelly) during the Treatment period and for at least 6 months after the last dose of study drug
  • For male patients who are partners of premenopausal women: agreement to use a barrier method of contraception during the Treatment period and for at least 6 months after the last dose of study drug
  • Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to participate
  • 19. Patients with measurable, progressive meningioma who received radiation therapy are potentially eligible but need to show evidence of progression at least 24 weeks from completion of radiation therapy
  • 20. Possible prior use of bevacizumab in the treatment of radionecrosis (3-24 months after radiosurgery or radiotherapy; 5mg/kg q14w, 4-6 cycles)

Who cannot take part

  • Prior antineoplastic therapy for meningioma
  • Subject incapacitated to understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted
  • Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort)
  • Are taking strong UGT1A9 inhibitors (e.g. mefenamic acid, diflunisal and niflumic acid)
  • Receiving additional, concurrent, active therapy for Meningioma outside of the trial
  • Any cerebrovascular accident (including transient ischemic attacks) within the last 6 months prior to initiation of study treatment
  • Any hemorrhage or bleeding event that is ≥ Grade 3 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE), Grade 2 intracranial hemorrhage, or persistent thrombotic/embolic event within 4 weeks prior to the start of study medication
  • Uncontrolled or severe cardiac disease (e.g., history of unstable angina, myocardial infarction, coronary stenting, or bypass surgery within the last 6 months prior to initiation of study treatment), symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation), requirement for inotropic support or use of devices for cardiac conditions (e.g.,pacemakers/defibrillators), or hypertension (participants with systolic blood pressure[BP] of > 160 mmHg or diastolic BP of > 100 mmHg despite optimal medical management are to be excluded)
  • Known history of hepatitis B, human immunodeficiency virus (HIV), or active hepatitis C infection requiring treatment with antiviral therapy. Note: HIV testing is not required in the absence of clinical suspicion
  • Disease outside the brain (ie. spinal cord or bone or metastasis to a distant organ)
  • Candidate for urgent palliative intervention for primary disease (e.g., impending herniation) as judged by the Investigator
  • History of allergy or hypersensitivity to any of the study treatments or any of their excipients
  • Serious, non-healing wound, ulcer, bone fracture, or abscess
  • Have an ongoing infection with severity of Grade 2 or above (CTCAE 5.0)
  • History of interstitial lung disease, history of slowly progressive dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis, or symptomatic pleural effusion
  • Active, known, or suspected auto-immune disease, including systemic lupus erythematosus, Hashimotos thyroiditis, scleroderma, polyarteritis nodosa, or auto-immune hepatitis
  • History of bleeding diathesis (irrespective of severity)
  • Uncontrolled intercurrent illness including (e.g., symptomatic ascites), but not limited to ongoing or active infection
  • Have any malabsorbition condition
  • Any condition that could make the subject noncompliant with the study procedures and/or study requirements, as judged by the Investigator (for example: cognitive impairment, psychiatric illness, etc)
  • In the presence of therapeutic intent to anticoagulate the patient:,INR or PT and aPTT not within therapeutic limits (according to the medical standard in the institution)
  • Persistent ≥ Grade 3 Lipase (> 2.0 - 5.0 x upper limit of normal [ULN] with signs or symptoms; > 5.0 x ULN and asymptomatic)
  • Persistent proteinuria > 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (≥ Grade 3, CTCAE 5.0)
  • History of another malignancy in the previous 3 years, with a disease-free interval of< 3 years. Patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible
  • Unable or unwilling to undergo brain MRI scans with intravenous (IV) gadolinium

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent meningiomas.

Read full original descriptionShow less

Small trials and case series suggest clinical relevant activity of several VEGF inhibitors such as sunitinib, bevacizumab and valatinib reporting a 6m-PFS rate of 42-64%. Indeed, VEGF and VEGF receptors (VEGFR) are regularly overexpressed in meningiomas and can correlate with outcome.

Regorafenib inhibits angiogenic receptor tyrosine kinases (RTKs) and is highly selective for VEGFR1/2/3; moreover Regorafenib inhibits PDGFRB, FGFR1 and oncogenic intracellular signalling cascades involving c-RAF/RAF1 and BRAF highly expressed in meningiomas.

Noteworthy, Regorafenib showed antitumor activity in vitro and in vivo in a recent study; indeed, Regorafenib showed significant inhibition of meningioma cell motility and invasion and in vivo, mice with orthotopic meningioma xenografts showed a reduced volume of signal enhancement in MRI following Regorafenib therapy; this translated in a significantly increased overall survival time (p<0.05) for Regorafenib treated mice.

Moreover, Regorafenib showed good efficacy in different cancer types, such as colorectal cancer, GIST, hepatocellular carcinoma and glioblastoma (REGOMA trial) , maintainingmaintaining a good quality of life.

The 2 groups in the trial

  • Arm A (interventional arm)Treatment being tested

    REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity

    Treatment: Regorafenib 40 MG Oral Tablet

  • Arm B (control arm)Existing treatment, for comparison

    Local Standard of Care until disease progression or unacceptable toxicity

    Treatment: Local Standard of Care

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Regorafenib for Recurrent Meningioma. A Multicenter, Randomized Phase II Study (MIRAGE Trial)
Plain-language title
Regorafenib for meningioma that has come backGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Publications
Record updated
30 September 2026